![]() |
Name |
Phomoarcherin B
|
Molecular Formula | C23H28O5 | |
IUPAC Name* |
(1S,13R,14S,19R)-10-hydroxy-1,14,18,18-tetramethyl-2,6-dioxapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-3,8,10-triene-7,17-dione
|
|
SMILES |
C[C@]12CCC(=O)C([C@@H]1CC[C@]3([C@@H]2CC4=C(C=C5C(=C4O3)COC5=O)O)C)(C)C
|
|
InChI |
InChI=1S/C23H28O5/c1-21(2)16-5-8-23(4)17(22(16,3)7-6-18(21)25)10-13-15(24)9-12-14(19(13)28-23)11-27-20(12)26/h9,16-17,24H,5-8,10-11H2,1-4H3/t16-,17+,22-,23-/m0/s1
|
|
InChIKey |
YHFZNBXTQFHWGR-TXKCWOHGSA-N
|
|
Synonyms |
Phomoarcherin B; CHEBI:67846; CHEMBL1773755; Q27136322
|
|
CAS | NA | |
PubChem CID | 52952104 | |
ChEMBL ID | CHEMBL1773755 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 384.5 | ALogp: | 3.6 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 72.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 28 | QED Weighted: | 0.653 |
Caco-2 Permeability: | -5.222 | MDCK Permeability: | 0.00001640 |
Pgp-inhibitor: | 0.094 | Pgp-substrate: | 0.041 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.52 |
Blood-Brain-Barrier Penetration (BBB): | 0.107 | Plasma Protein Binding (PPB): | 94.06% |
Volume Distribution (VD): | 0.771 | Fu: | 7.13% |
CYP1A2-inhibitor: | 0.407 | CYP1A2-substrate: | 0.867 |
CYP2C19-inhibitor: | 0.027 | CYP2C19-substrate: | 0.471 |
CYP2C9-inhibitor: | 0.262 | CYP2C9-substrate: | 0.767 |
CYP2D6-inhibitor: | 0.398 | CYP2D6-substrate: | 0.298 |
CYP3A4-inhibitor: | 0.147 | CYP3A4-substrate: | 0.2 |
Clearance (CL): | 19.473 | Half-life (T1/2): | 0.701 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.427 |
Drug-inuced Liver Injury (DILI): | 0.045 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.826 | Maximum Recommended Daily Dose: | 0.786 |
Skin Sensitization: | 0.254 | Carcinogencity: | 0.66 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.589 |
Respiratory Toxicity: | 0.973 |